NCT05905705 Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy
| NCT ID | NCT05905705 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Treatment Resistant Depression |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-03-07 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2023-03-07 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Electroconvulsive therapy (ECT) alleviates treatment-resistant depression (TRD) through repeated generalized seizures. The goal of this study is to evaluate how ECT impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.
Eligibility Criteria
Inclusion Criteria: * Referral for initial ECT index course for Treatment-Resistant Depression (TRD), unipolar major depressive disorder or bipolar depression. Historic failure of response or remission to at least two antidepressant medications of sufficient dose and duration will be used for TRD diagnostic. Exclusion Criteria: * Diagnoses of schizophrenia or schizoaffective disorders. * Subjects who are unable to tolerate the Dreem device for sleep recordings will be excluded from the study.
Contact & Investigator
MohammadMehdi Kafashan
PRINCIPAL INVESTIGATOR
Washington University School of Medicine in St. Louis
Frequently Asked Questions
Who can join the NCT05905705 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 65 Years, studying Treatment Resistant Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05905705 currently recruiting?
Yes, NCT05905705 is actively recruiting participants. Contact the research team at greenspan@wustl.edu for enrollment information.
Where is the NCT05905705 trial being conducted?
This trial is being conducted at St Louis, United States.
Who is sponsoring the NCT05905705 clinical trial?
NCT05905705 is sponsored by Washington University School of Medicine. The principal investigator is MohammadMehdi Kafashan at Washington University School of Medicine in St. Louis. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.